Tetraphase Pharmaceuticals
Antibiotics to treat multi-drug resistant bacterial infections.
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 111 % | (63 %) | 43 % | 60 % | 38 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1278 %) | (384 %) | (957 %) | (290 %) | (113 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1278 %) | (379 %) | (1057 %) | (330 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 941 % | 249 % | - | - | - | - |
Source: Company filings or news article
Related Content
Tetraphase Pharmaceuticals is dedicated to addressing one of the most critical threats to global health: antibiotic resistance. The company specializes in the development of novel antibiotics aimed at treating infections caused by multidrug-resistant (MDR) bacteria. Utilizing proprietary chemistry technology, Tetraphase is creating multiple tetracycline-based antibiotics that show promise against some of the most challenging MDR bacteria. The company's mission is to make these innovative antibiotics accessible to all patients who need them, thereby potentially changing the course of antibiotic resistance for millions at risk.
Tetraphase operates in the pharmaceutical and biotechnology market, primarily serving healthcare providers, hospitals, and patients who are in dire need of effective treatments against resistant bacterial infections. The business model revolves around research and development (R&D) of new antibiotic drugs, followed by clinical trials, regulatory approvals, and eventual commercialization. Revenue is generated through the sale of these antibiotics, as well as potential out-licensing agreements for their pipeline products.
Keywords: antibiotic resistance, multidrug-resistant bacteria, tetracycline-based antibiotics, proprietary chemistry, healthcare providers, biotechnology, pharmaceutical R&D, clinical trials, regulatory approvals, out-licensing.